KYOWA-KIRIN
31.7.2024 09:01:31 CEST | Business Wire | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the Polish Ministry of Health has approved the reimbursement of POTELIGEO® (mogamulizumab) in second-line monotherapy for adult patients with Stage IB and above mycosis fungoides (MF), and Sézary syndrome (SS).
MF and SS are two subtypes of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin and can have debilitating physical, emotional and social challenges.1 MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs.2
With an average time to diagnosis of 3-4 years, MF is typically characterised by skin symptoms including patches or plaques, skin redness and tumours.3,4 SS is much rarer, accounting for around 5% of CTCLs,5 and is more aggressive, causing severe itching, erythroderma, intense scaling of the skin and frequent hair loss.6
Jeremy Morgan, President of Kyowa Kirin International, commented: “I am delighted that the Ministry of Health has agreed to reimburse POTELIGEO for MF and SS patients in Poland. Our purpose at Kyowa Kirin is to make people smile, and I am proud to see us living this purpose and achieving such an important milestone for the CTCL community. With a commitment to delivering life changing value for people impacted by under-diagnosed and under-served diseases, approval in Poland now means mogamulizumab is reimbursed in almost 30 countries across the EMEA region, and is a critical step in helping to meet the needs of people living with CTCL.”
Kyowa Kirin International and Swixx BioPharma AG signed a Promotion and Distribution Agreement in October 2022. Under the terms of the agreement, Swixx exclusively markets, promotes and distributes mogamulizumab in Poland.
Michał Opuchlik, General Manager of Swixx BioPharma Poland, commented: “The positive reimbursement decision of the Polish Ministry of Health is surely an important achievement for patients in Poland suffering from CTCL. We are very proud that, thanks to the great cooperation between Swixx BioPharma, Kyowa Kirin and all our stakeholders in Poland, we were able to ensure that patients now have access to this medicine, that received the FDA's breakthrough therapy designation several years ago. At Swixx BioPharma we are proud of our mission to bring the innovative therapies of our partners to patients in need and this milestone once again positions Swixx BioPharma Poland among the leading companies securing access to innovative treatments in our country.”
About Poteligeo (mogamulizumab)
Mogamulizumab is a first-in-class humanised monoclonal antibody directed against CC-chemokine receptor 4 (CCR4), a protein consistently expressed on cancerous cells seen in both MF and SS,7-9 once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.10
About MF and SS
MF and SS are two subtypes of CTCL, which is itself a rare form of non-Hodgkin’s lymphoma that presents and persists in the skin.1 CTCL is treatable, but is not generally considered to be curable, and there has been a clear unmet need for novel treatment options. As well as the obvious impact of symptoms upon patients, there can be significant erosions to quality of life for those caring for an individual living with CTCL.11
MF and SS are characterised by localisation of cancerous white blood cells called T lymphocytes (T cells), to the skin.12 These cancerous T cells consistently express a protein called CCR4, which enables them to move from the blood to the skin.7-9 When these cancerous T cells move to the skin, this results in the visible early skin symptoms of red patches or plaques which can resemble psoriasis or eczema in the early stages of the disease.13 Later, for some patients, skin involvement may evolve to include tumours or reddening of the majority of the skin’s surface (erythroderma).
MF—the most common CTCL subtype—accounts for approximately 60% of all CTCLs2 and is typically indolent, characterised by skin symptoms including patches or plaques, skin redness and tumours.3,4 SS is much rarer, accounting for around 5% of CTCLs,5 and is more aggressive,6 with high levels of blood involvement.5 It can cause severe itching, erythroderma, intense scaling of the skin and frequent hair loss.6 CTCL can take, on average, between 2 and 7 years for individuals to receive a confirmed diagnosis.13
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International.
You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com
About Swixx BioPharma AG
Swixx BioPharma is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof.
For more information about Swixx BioPharma, please visit: www.swixxbiopharma.com
References
1Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204.
2Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
3Scarisbrick, J, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2019;181(20):350–357.
4Demierre M-F, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life. Cancer. 2006;107(10):2504-2511.
5Trautinger F, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosisfungoides/Sézary syndrome - Update 2017. European Journal of Cancer. 2017;77:57–74.
6Lymphoma Coalition. Cutaneous lymphoma – a patient’s guide. Available at: https://lymphomacoalition.org/wpcontent/uploads/Cutaneous_lymphoma_-_patients_guide_-.pdf. Last accessed: July 2024
7Ferenczi K, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–10.
8Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505–11.
9Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625–34.
10Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
11Williams et al (2020) – Health state utilities associated with caring for an individual with CTCL. Journal of Medical Economics. 2020; 23(10):1142-1150.
12Scarisbrick JJ, Prince M, Vermeer MH, et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015;33(32):3766-3773.
13Cutaneous Lymphoma Foundation, Lymphoma Action and Lymphoma Coalition Europe. Cutaneous lymphoma – a patient’s guide. 2019. Available from: https://lymphomacoalition.org/wpcontent/uploads/Cutaneous_lymphoma_-_patients_guide_-.pdf. Last accessed: July 2024.
KKI/INT/MOG/1166
Date of preparation: July 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731235221/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Elects German Herrera as New Chair28.1.2026 20:01:00 CET | Press release
Herrera succeeds Michael Ensser, who will remain an active member of the Firm after his term in a planned transition. Egon Zehnder, the world’s premier leadership advisory firm, today announced that, in accordance with its established governance and three-year election cycle, German Herrera has been elected as the Firm’s next Chair by its worldwide partnership. Herrera will assume the role effective March 1, 2026. He will succeed Michael Ensser, who has held the position since 2022, in a planned succession at the conclusion of his regular term. Herrera joined the Firm in 1998 in Bogotá and has helped shape the Firm’s global presence, taking on a broad range of leadership roles, from co-leading the Global Family Business Advisory Practice to serving on the Executive Committee and the Market Council. Most recently, Herrera has guided Egon Zehnder’s U.S. market through a period of impressive growth and transformation, which today includes 15 offices and more than 150 consultants. As the f
De' Longhi Group - Record Preliminary 2025 Revenues of €3.8 Billion, up 10.4% at Constant Exchange Rates28.1.2026 19:25:00 CET | Press release
The Group closed 2025 with brilliant results and solid growth at constant currency across both divisions throughout the year, further confirmed by an organic expansion of 8.2% in Q4 Below are the preliminary 2025 revenues for the De’ Longhi S.p.A. Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128191504/en/12 months, revenues at € 3,801.5 million, growing at 8.7% (+10.4% at constant currency); fourth quarter, revenues at € 1,340.0 million, growing at 5.7% (+8.2% at constant currency). Fabio de' Longhi, CEO of the Group, stated: "The Group achieved solid growth at constant currency of 10.4% in 2025, characterized by consistent results throughout the year. We are particularly pleased with the excellent performance achieved in the fourth quarter, which successfully overcame the challenges posed by the current market environment. The household division consolidated its recent growth momentum during the quarter, with or
Organon Completes Divestiture of JADA® System to Laborie28.1.2026 18:45:00 CET | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms. Indications for Use The JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Contraindications Ongoing intrauterine pregnancy Untreated uterine rupture Unresolved uterine inversion Current cervical cancer Known uterine anomaly Current purulent infection of vagina, cervix, or uterus For C-sections: Cervix <3 cm dilated before use of JADA Warnings Avoid excessive force when inserting JADA into the uterus or trauma to uterine wall may occur, including perforation. The safety and effectiveness of the JADA System in delivery at a gestational age <34 weeks or, if multiples, uter
Laserfiche Expands AI Data Capture with Auto-Classification to Transform Data into Business Intelligence28.1.2026 16:00:00 CET | Press release
New intelligent features automatically organize and classify documents, transforming how organizations manage information at scale. Laserfiche — the leading SaaS provider of intelligent content management — today announced major enhancements to its AI-powered data extraction tool, Smart Fields. The update introduces automated document classification and tagging, allowing organizations to move from unstructured content to informed decisions in seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128228490/en/ Using natural language prompts instead of rigid, ruled-based OCR, Smart Fields can now identify document type — such as invoices, taxpayer identification forms, or student transcripts — and automatically apply the correct metadata template using AI. Users can also use Smart Fields to automatically add informational and security tags to files that meet certain criteria, defined using a natural language prompt. Users
Intersolar Africa 2026 to Position Nairobi as East Africa’s Key Hub for Solar and Energy Storage28.1.2026 15:20:00 CET | Press release
East Africa is emerging as one of the world’s most dynamic regions for solar power and battery storage. On 3–4 February 2026, Intersolar Africa will take place at the Sarit Expo Centre in Nairobi, expanding from the successful Intersolar Summit Africa in 2025 into a full international exhibition and conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128955267/en/ Intersolar Africa will take place on February 3-4 in Nairobi. East Africa’s Energy Market and Opportunities Rapid population growth, industrialization, and rising electricity demand are putting pressure on power systems across East Africa. Limited generation capacity, grid instability, and high electricity costs constrain economic growth. Solar photovoltaics combined with energy storage have emerged as the most cost-effective and scalable solution to expand capacity, stabilize supply, and strengthen long-term energy security for businesses and communities
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom